Business Growth Story

2010

• Company formation under Insud Pharma (Europe).
• Acquisition of PharmaADN, mAbxience´s Argentina R&D platform.
2012

• mAbxience Argentina biomanufacturing facility inauguration.
2014

• Acquisition of Genhelix, a Spanish biotech R&D center.
• First launch of Rituximab (Novex®, Argentina).
2015

• Spain biomanufacturing and R&D center inauguration.
2016

• First launch of Bevacizumab (Bevax®, Argentina).
• Global consortium established for the development of palivizumab biosimilar*.
2017

• Expansion of global access of Rituximab & Bevacizumab.
• EMA GMP certification granted to Spanish facility.
2018

• Alliances with leading pharma companies in EU, USA, and Australia.
2019

• New partnerships in EU, Japan, Russia, Canada and other key markets.
• Partnered worlwide with Bevacizumab biosimilar.
2020

• New state-of-the-art mAbxience biomanufacturing facility opening in Argentina.
• Commercial presence via B2B partners in than 100+ markets.
2021

• EMA approval for Bevacizumab.
• Manufacturing agreement for Astrazeneca Covid-19 vaccine.
• Addition of Universal farma completed vertical integration from fermentation to.

GMP: Good Manufacturing Practices

EMA: European Medicines Agency

FDA: US Food Drug Administration

*Programme endorsed by the World Health Organization (WHO) for the treatment of Respiratory Sincitial Virus in pediatric population